Last reviewed · How we verify

Triferic AVNU

Rockwell Medical Technologies, Inc. · FDA-approved active Small molecule

Triferic AVNU is an iron replacement therapy that delivers iron directly into the bloodstream during hemodialysis to treat iron deficiency anemia.

Triferic AVNU is an iron replacement therapy that delivers iron directly into the bloodstream during hemodialysis to treat iron deficiency anemia. Used for Iron deficiency anemia in patients with chronic kidney disease on hemodialysis.

At a glance

Generic nameTriferic AVNU
Also known asFerric Pyrophosphate Citrate (FPC), FPC
SponsorRockwell Medical Technologies, Inc.
Drug classIron replacement agent
TargetIron (Fe3+) delivery system
ModalitySmall molecule
Therapeutic areaNephrology / Hematology
PhaseFDA-approved

Mechanism of action

Triferic AVNU (ferric pyrophosphate citrate) is administered intravenously during hemodialysis sessions and replaces iron lost during dialysis and due to chronic kidney disease-related blood loss. It works by providing bioavailable iron that is incorporated into hemoglobin and myoglobin, thereby correcting iron deficiency anemia in patients with chronic kidney disease on hemodialysis without requiring separate iron infusions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: